The combined effects of etanercept plus methylprednisolone on pancreatic oxidative stress in acute pancreatitis induced by cerulein

Murat Günay*a, Erol Kılıçb, Ramazan Amanvermez*a

aDepartment of Biochemistry, Medical Faculty, Ondokuz Mayıs University, Samsun, Turkey
bDepartment of General Surgery, Medical Faculty, Ondokuz Mayıs University, Samsun, Turkey

ARTICLE INFO

ABSTRACT

Whether etanercept plus methylprednisolone reduce pancreatic oxidative stress and injury during pancreatitis is unknown well. The aim of this study was to examine the therapeutic effects of etanercept and methylprednisolone (MP) on acute pancreatitis and oxidative stress in acute pancreatitis (AP) induced by cerulein in a rat model. The study was performed with 48 rats divided into 6 groups (n = 8/group): 1-sham, 2-cerulein-induced pancreatitis (over 10 hours), 3-cerulein-pancreatitis (over 20 hours), 4-etanercept (5 mg/kg, i.p.), 5-methylprednisolone (10 mg/kg, i.m.), 6-etanercept plus methylprednisolone. Also, the rats in groups 4, 5, and 6 were cerulein-induced pancreatitis at 20 hours. After the treatment, the pancreas and blood were taken for histopathological and biochemical analysis. All cerulein-treated rats developed biochemical and pathological acute pancreatitis after 10-20 hours. The markers of oxidative stress such as protein carbonyls, lipid peroxidation, and myeloperoxidase (mPO) in the pancreas tissues were increased in the group 2 and 3, but these were lower in etanercept and MP-treated rats compared to groups 3. Pancreatic mPO activity was considerably reduced in pancreas tissues at 20 h after the administration of etanercept plus methylprednisolone in the group 6 compared to group 3. In AP induced by cerulein, the treatment of etanercept plus methylprednisolone may ameliorate pancreatic oxidative stress in rats.


© 2011 OMU All rights reserved

1. Introduction

The etiological basis of AP is multifactorial (Steer, 2008). Usually AP known as a pancreatic disease is an inflammation initially localized in the pancreatic tissue which may cause to local and systemic complications in the patients. The mortality due to AP is approximately 10%, but this estimate raise up to 20-30% in the severe forms of the disease due to multiple organ failure. Progress in medicine, mostly supportive and antibiotic therapy and surgery all has contributed to reduce mortality and morbidity rates in severe AP in the past decades (Pereda et al., 2006; Bang et al., 2008; Steer, 2008). However, no specific effective treatment has been reported in the clinical trials so far.

There is considerable evidence that the inflammation contributes significantly to the developing pancreatic damage by mechanisms like infiltration of inflammatory cells (granulocytes, monocytes/macrophages) and the release of toxic substances such as reactive oxygen species produced in excess, lipid peroxidation, protein oxidation and their harmful compounds, and pro-inflammatory cytokines (e.g. IL-1, IL-6 and TNF-α) (Reinheckel et al., 1998; Kyu et al., 2003; Pereda et al., 2006). Actived macrophages release pro-inflammatory cytokines in response to the local damage of the pancreas. Moreover, increased oxidative stress appeared during pancreatitis in the course of AP (Dabrowski et al., 1999; Telek et al., 1999; Abu-Zidan et al., 2000; Shi et al., 2005). At present there are evidences of a synergy or the relationship between oxidative stress and pro-inflammatory cytokines in development of the inflammatory response in AP (Pereda et al., 2004; Pereda et al., 2006). In relation to this issue, Pereda et al have shown that simultaneous inhibition of TNF-α production and xanthine oxidase activity blocks to a great extent the local and systemic inflammatory response in AP (Pereda et al., 2004). In addition, inflammation and oxidative stress both occur in the pancreas during the early stages of acute pancreatitis (Dabrowski et al., 1999).

It seems that inflammation is a dominant phenomenon in the early stage of AP and during the course of the disease. The patient’s acute pancreatitis may be resolved whether pancreatic inflammation could be blocked or reduced by anti-inflammatory agents. Effective therapeutic agents are required to reduce morbidity and mortality rate of acute pancreatitis associated life loss. Etanercept which is a soluble TNF-α binding agent, competitively inhibits the binding of TNF
molecules to TNF receptor sites. The binding of etanercept to TNF renders the bound TNF biologically inactive, resulting in a significant reduction in inflammatory activity (Mallo et al., 2007). Like most corticosteroids, methylprednisolone is typically used for its anti-inflammatory activity. The function of etanercept plus MP is unclear as a therapeutic agent in the prevention and treatment of AP (Bang et al., 2008). The purpose of present study was to investigate whether the combined effects of etanercept plus MP could prevent, or decrease pancreatic oxidative stress in cerulein-induced AP, as defined by the markers of oxidative stress.

2. Materials and Methods
Sprague-Dawley male rats, weighing 250-270 g were used in all experiments. The rats were housed in per cage with wood chip bedding and fed on standard laboratory chow and water ad libitum. They were maintained on a 12 h light: dark cycle with a constant room temperature at 22 ± 1 °C. This study was carried out in the Experimental Research Center, Ondokuz Mayis University, Samsun, Turkey. The local ethical committee of Ondokuz Mayis University approved all animal procedures, and the experimental protocol.

Animal treatment: The rats were randomized into six groups (n = 8/group): 1. Sham-treated in which identical treatments to group 2 were performed, except that the saline was administered instead of cerulein; 2. Cerulein-induced pancreatitis (at 10 h): Rats were treated hourly (xs5) with cerulein (total 80 µg/kg, i.p., suspended in saline solution) and an additional 5 hours was allowed to pass for a complete pancreatitis induction at 10 h; 3. Cerulein-pancreatitis (at 20 h): Identical to the group 2, an extra 10 hours was waited for the continuation of induced pancreatitis; 4. Etanercept group, except for the administration of etanercept (5 mg/kg, i.p., dissolved in saline solution) which was given hourly (two times) at the end of 5th h after the last cerulein application; 5. Methylprednisolone group, MP (10 mg/kg, i.m.) was given hourly (two times) at the end of 5th h after the last cerulein application. 6. Etanercept plus methylprednisolone group, the administration of methylprednisolone (10 mg/kg, i.m.) along with etanercept (5 mg/kg, i.p.) which were given hourly (two times) at the end of 5th h after the last cerulein application. At the end of experiments, the rats were anaesthetised by intramuscular injection of ketamine. After blood samples were obtained by direct intra-cardiac puncture with an injector, all rats were sacrificed by exsanguinations under anaesthesia at 10 h (group 2) and 20 h (groups 3,4,5, and 6) after the induction of pancreatitis. Also rats were killed at 20 h in the group 1. The pancreas was resected with midline laparotomy under sterile conditions. A segment of pancreas was washed in a sterile conditions. A segment of pancreas was washed in 1. The pancreas was resected with midline laparotomy under...

Histopathological study: A part of pancreas was fixed with 24 hours buffered neutral formalin and then processed for the routine tissue follow-up. The tissues were embedded in paraffin blocks and cut into 4-6 µm thick sections, and then stained with Hematoxylin & Eosin. The stained sections were evaluated by a pathologist who was uninformed about the groups. The method of Rongione et al., (1997) was used for scoring the degree of oedema, inflammation, vacuolization, necrosis in the pancreas.

Biochemical measurements: The markers of oxidative stress marked in this study include protein carbonyls, a marker of protein oxidation; malondialdehyde, a marker of lipid peroxidation; and myeloperoxidase, a neutrophil enzyme that produces oxidants. To determine tissue concentrations of lipid peroxidation, protein carbonyls, myeloperoxidase and protein, a part of rat pancreas was excised, weighed and it was minced and homogenized well in liquid nitrogen immediately after excision, and then the homogenate was sonicated for 60 s at 220 V (Fisher, Sonic Dismembrator; Model 300) in each cold assay buffer. All chemicals used for the assays were of analytical grade and purchased from Sigma Chemical Co.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Protein Carbonyls (nmol/mg protein)</th>
<th>MDA (µmol/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. (n=8)</td>
<td>0.385 ± 0.163</td>
<td>0.097 ± 0.032</td>
</tr>
<tr>
<td>2. (n=8)</td>
<td>0.605 ± 0.218</td>
<td>0.320 ± 0.208</td>
</tr>
<tr>
<td>3. (n=8)</td>
<td>0.804 ± 0.299</td>
<td>0.533 ± 0.183</td>
</tr>
<tr>
<td>4. (n=8)</td>
<td>0.733 ± 0.138</td>
<td>0.208 ± 0.076</td>
</tr>
<tr>
<td>5. (n=8)</td>
<td>0.578 ± 0.171</td>
<td>0.138 ± 0.023</td>
</tr>
<tr>
<td>6. (n=8)</td>
<td>0.513 ± 0.103</td>
<td>0.112 ± 0.016</td>
</tr>
</tbody>
</table>

In the pancreatic homogenate, lipid peroxidation was estimated spectrophotometrically by the thiobarbituric acid-reactive substance (TBARS) method with slight modifications (Singh et al., 2000) and expressed in terms of malondialdehyde (MDA) formed per mg protein. Measurements of protein (carbonyl) oxidation in the pancreas homogenate samples were made by the method of Evans et al., (1999) with slight modifications. Carbonyl concentration (nmol mg-1 of protein)= nmol ml-1 of carbonyl groups/protein concentration in mg ml-1. The usefulness of measuring mpo activity to assess neutrophil infiltration has been previously reported (Genovese et al., 2006), the pancreatic homogenate levels of mpo were determined by using hydrogen peroxide as a substrate for the enzyme. One unit of mpo activity is defined as that degrading 1 µmol of peroxide per minute at 25 °C and is expressed in units per mg protein. The protein concentration was determined by the method of Lowry et al., (1951).

Statistical analysis: Data were controlled for normality assumption, they were normally distributed therefore parametric statistical analysis were used to evaluate data. So, the...
statistical evaluations were done by Univariate Analysis of Variance. Variances were homogeneously distributed according to Levene test, and then the pairwise comparisons were done by Turkey or Tamhane test. Results were expressed as mean ± standard deviation. Differences were considered statistically significant at $P$ values $< 0.05$.

3. Results
Effects of etanercept plus MP on pancreatic oxidative stress during experimental AP.

Levels of pancreatic protein oxidation and lipid peroxidation were found to be lower in pancreas tissue from the animals in the group 6 with the application of etanercept plus MP than those of the group 3 (Table 1). An evidence of AP is inflammation that is related to the accumulation of inflammatory cells in the pancreas, which augment the tissue damage. Therefore, we have determined higher inflammation and necrosis in the group 3 compared to sham-treated group. The activity of mpo is a quantitative measure of neutrophil infiltration in pancreas tissue. The levels of mpo was significantly higher in acute pancreatitis group than that of the sham-treated group ($P < 0.001$). The activity of mpo was considerably suppressed by etanercept plus MP treatment (Fig 1.).

After acute pancreatitis induction, protein oxidation and lipid peroxidation were increased during acute pancreatitis. Therefore, oxidative stress markers in pancreas and serum concentrations of amylase and lipase were much higher and pancreatic lesions more severe in acute pancreatitis induced by cerulein in group 3. However, their levels were attenuated by the administration of etanercept plus MP in group 6.

4. Discussion
Acute pancreatitis is an inflammatory process in the pancreas, and oxygen free radicals have been implicated as an important factor in the associated tissue destruction in both the initiation and progression of AP (Telek et al., 1999; Kyu et al., 2003; Shi et al., 2005; Genovese et al., 2006). In addition, oxidative stress was documented in pancreatic tissue by means of methods showing accumulation of products of lipid peroxidation and occurrence of oxidatively modified proteins, with concomitant depletion of enzymatic and low molecular weigh antioxidants (Reinheckel et al., 1998; Dabrowski et al., 1999). Abu-Zidan et al. and Kiziler et al. have indicated that oxidative stress is a feature within the first 24 h of the onset of AP (Abu-Zidan et al., 2000; Kiziler et al., 2008).

In scientific literature, there are many experimental evidences of a synergy between oxidative stress and pro-inflammatory cytokines in the development of the inflammatory response in AP (Denham et al., 1997; Pereda et al., 2004; Pereda et al., 2006). Moreover, pro-inflammatory cytokines and oxidative stress trigger common signal transduction pathways that lead to amplification of the inflammatory cascade (Shi et al., 2005; Pereda et al., 2006). Furthermore, pro-inflammatory cytokines, in particularly TNF-α, and oxidative stress promote each other generating a vicious circle resulting in cell death and increased vascular permeability with tissue edema (Dean et al., 1997; Reinheckel et al., 1998; Kyu et al., 2003). It has been shown that the levels of oxidative damage markers MDA and protein carbonyls are increased in tissue and plasma in acute pancreatitis (Kiziler et al., 2008). In our study, protein oxidation and lipid peroxidation were found to be higher in the groups 2 and 3 compared to sham-treated group. By the way, pancreatic protein carbonyls and MDA levels were lower by 8.83% and 41% in etanercept-treated rats than those of the group 3. Also, the activity of mpo seems to be lower in the groups 4, 5 and 6 received treatments than those of acute pancreatitis groups. In an experimental study, Yilmaz et al. (2009) reported that etanercept caused marked decreases in pancreatic tissue MDA levels and mpo activities in treated groups with taurocholate-induced acute pancreatitis. In accordance to these findings, TNF-α reduction by etanercept might lead to ameliorate pancreatic oxidative stress in AP.

Corticosteroids are widely used for the suppression of inflammatory responses (Barnes, 1998). Currently these drugs are being used in a wide variety of inflammatory diseases affecting many organs. Kimura et al. reported that glucocorticoids were attenuated pancreatic damage by protecting acinar cells during cerulein-induced AP (Kimura et al., 1998). MP (5-40 mg/kg, 6-72 h) pre-treatment reduced the serum amylase activity, the pancreatic levels of TNF-α and IL-6, the pancreatic mpo activity and morphological parameters of the
disease during CCK-induced AP in rats (Rakonczay et al., 2003). In our study, MP at the dose of 10 mg/kg in cerulein-induced AP was led to be decreased pancreatic protein oxidation (by 28.1%) and lipid peroxidation (by 60.9%) levels in the group 5 compared to group 3 (Table 1). Similarly, the activity of mpo was reduced significantly in the group 5 given MP. As a result of these findings, MP can have a protective effect against pancreatic oxidative stress and damage in AP. Moreover, as cited in literature: If direct correlation between oxidative stress and severity of pancreatitis have been reported, etanercept and MP exert potent anti-inflammatory effects in AP (Rakonczay et al., 2003; Malleo et al., 2007). In our study, pancreatic protein carbonyls and MDA values were decreased in the pancreas at 20 h after the treatment of these drugs. Apart from these results, the activity of mpo was statistically reduced in the group 6 compared to group 3 (Table 1 and Fig. 1). Based on these results we hypothesize that etanercept plus MP influences the oxygen radical formation and minimizes protein oxidation and lipid peroxidation. Inflammatory cells in particularly neutrophils which play a crucial role in the development and full manifestation of AP, are very active in this disease (Genovese et al., 2006). Oxidative stress may be closely associated with inflammatory process and the severity of AP (Kyu et al., 2003). The antioxidant effects of these drugs may partly be due to inhibition of neutrophil chemotaxis. Possibly, etanercept plus MP therapy in inflamed pancreatic tissue may result in a significant reduction in inflammatory activity. Our previous study report has indicated that a decrease in pancreas damage histopathologically when using etanercept and MP for pancreatic injury in cerulein-induced AP (Kilic et al., 2010).

In conclusion, these results support that the treatment of etanercept plus MP cause the attenuation of pancreatic oxidative stress in cerulein-induced AP. Based on the results of recent studies, it is mentioned that treatments of etanercept and MP have preventive effects on AP development and its complications. So they may be useful in biliopancreatic surgery and endoscopic retrograde cholangiopancreatography (ERCP). The combination of etanercept plus MP might be useful in the therapy of conditions associated with AP as the drugs of protective against pancreatic damage. Studies from different areas involving high number of animals, pro-inflammatory cytokines like TNF-α and the other oxidative stress markers are needed to confirm the findings of the present study.

Acknowledgements
The authors thank Dr. Leman Tomak for providing the statistical advice.

REFERENCES


